Depletion of UBE2C in cancer cells by UBE2C-siRNA redistributes the cell cycle phases [14,25], while bortezomib or cell-cycle inhibitor-779 (CCI-779) stabilizes mitotic cyclins and prevents cell cycle progression via attenuation of UBE2C transcription and mRNA stability [30,32]. The gene discussed is UBE2C; the disease is cancer.